Fawipirawir (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fawipirawir" in Polish language version.

refsWebsite

Global rank Polish rank

2^nd place

6^th place

4^th place

7^th place

4,294^th place

205^th place

399^th place

2,234^th place

260^th place

867^th place

831^st place

1,020^th place

138^th place

2,672^nd place

chinadaily.com.cn

ZhangZ. Yangfei ZhangZ., Potential coronavirus drug approved for marketing, [w:] China Daily [online], 17 lutego 2020 [dostęp 2020-10-12] (ang.).

Yin-XiaoY.X. Du Yin-XiaoY.X., Xiao-PingX.P. Chen Xiao-PingX.P., Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, „Clinical Pharmacology and Therapeutics”, 2020, DOI: 10.1002/cpt.1844, PMID: 32246834 (ang.).
KimiyasuK. Shiraki KimiyasuK., TohruT. Daikoku TohruT., Favipiravir, an anti-influenza drug against life-threatening RNA virus infections, „Pharmacology & Therapeutics”, 2020, s. 107512, DOI: 10.1016/j.pharmthera.2020.107512, PMID: 32097670, PMCID: PMC7102570 (ang.).
DaoudaD. Sissoko DaoudaD. i inni, Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, „PLOS Medicine”, 13 (3), 2016, e1001967, DOI: 10.1371/journal.pmed.1001967, PMID: 26930627, PMCID: PMC4773183 (ang.).
ZhinanZ. Jin ZhinanZ. i inni, The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-triphosphate towards influenza A virus polymerase, „PLoS One”, 8 (7), 2013, e68347, DOI: 10.1371/journal.pone.0068347, PMID: 23874596, PMCID: PMC3707847 (ang.).

Favipravir, [w:] DrugBank [online], University of Alberta, DB12466 [dostęp 2020-05-01] (ang.).

Yin-XiaoY.X. Du Yin-XiaoY.X., Xiao-PingX.P. Chen Xiao-PingX.P., Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, „Clinical Pharmacology and Therapeutics”, 2020, DOI: 10.1002/cpt.1844, PMID: 32246834 (ang.).
KimiyasuK. Shiraki KimiyasuK., TohruT. Daikoku TohruT., Favipiravir, an anti-influenza drug against life-threatening RNA virus infections, „Pharmacology & Therapeutics”, 2020, s. 107512, DOI: 10.1016/j.pharmthera.2020.107512, PMID: 32097670, PMCID: PMC7102570 (ang.).
DaoudaD. Sissoko DaoudaD. i inni, Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, „PLOS Medicine”, 13 (3), 2016, e1001967, DOI: 10.1371/journal.pmed.1001967, PMID: 26930627, PMCID: PMC4773183 (ang.).
ZhinanZ. Jin ZhinanZ. i inni, The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-triphosphate towards influenza A virus polymerase, „PLoS One”, 8 (7), 2013, e68347, DOI: 10.1371/journal.pone.0068347, PMID: 23874596, PMCID: PMC3707847 (ang.).